---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-109256"
form_type: "8-K"
ticker: "SLS"
cik: "0001390478"
company_name: "SELLAS Life Sciences Group, Inc."
filed_at: "2023-10-16T23:59:59+00:00"
generated_at: "2026-06-09T23:09:04.986231+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# SELLAS reports positive Phase 2a topline data for SLS009 in AML; first patient achieved complete response

## Summary
- First of 5 enrolled r/r AML patients achieved complete response, remains alive in 5th month of treatment.
- All 5 patients alive at last follow-up; 4 continue treatment; anti-leukemic effects seen in all.
- No significant safety issues observed at 45 mg dose level; median OS for venetoclax-failure AML is ~2.5 months.
- SLS009 is first CDK9 inhibitor to achieve CR in combination with AZA/VEN in venetoclax-resistant AML.
- Topline data for 60 mg dose expected later this quarter; multiple registrational opportunities cited.

## SEC filing metadata
- accession: 0001104659-23-109256
- form_type: 8-K
- ticker: SLS
- cik: 0001390478
- company_name: SELLAS Life Sciences Group, Inc.
- filed_at: 2023-10-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1390478/000110465923109256/0001104659-23-109256-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1390478/000110465923109256/tm2328502d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-109256
- JSON: https://secwatch.observer/filing/0001104659-23-109256.json
- Plain text: https://secwatch.observer/filing/0001104659-23-109256.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.